Introduction
============

Ginger is a Chinese medicine (CM) used as a food and as a medicine, and is often used to treat cold syndrome through the property of warming. Dried ginger (Zingiberis Rhizoma, GanJiang, GJ) is processed from fresh ginger and is also commonly used in CM. It is used to treat cold asthma by "warming the stomach to dispel cold, warming the lung to resolve fluid," and it has significant anti-inflammatory, anticancer, antipyretic, and antioxidant properties ([@B3]; [@B46]). A previous report showed that phenolic compounds in GJ can prevent and treat asthma by inhibiting expression of TH2 and TH1 cells ([@B21]). However, CM in clinical application is mainly based on CM prescription.

Linggan Wuwei Jiangxin (LGWWJX) prescription originated from the "Jingui Yaolüe" ("Synopsis of Golden Chamber"), written by Zhongjing Zhang, who was one of the most famous Chinese doctors during the Han Dynasty. LGWWJX has been used to treat cold asthma for over a 1000 years. It consists of Zingiberis Rhizoma (Gan Jiang, GJ, monarch drug), Poria (Fu Ling, FL), Glycyrrhizare Radix Et Rhizoma (GanCao, GC), Asari Radix Et Rhizoma (Xi Xin, XX), and Schisandrae Chinensis Fructus (Wu Wei Zi, WWZ). Interestingly, GJ is the main component in LGWWJX, which can also be used to treat cold asthma. Our previous study demonstrated significant differences between various processed ginger products on blood stasis syndrome ([@B16]). In this study, we proposed that there were differences in the compatibility of GJ for treatment of disease.

Metabolomics is a part of biological systems to monitor global small molecule endogenous metabolite changes induced by biochemical reactions under a given set of physiological conditions *in vivo*. It is a useful technique for study of CM. As metabolomics provides a comprehensive assessment of cellular pathways, it has recently attracted much attention in the treatment of diseases with CM ([@B50]; [@B44]; [@B35]). Gas chromatography--mass spectrometry (GC--MS) is a technique used for metabolomics analysis, which is characterized by high sensitivity and numerous available databases. GC--MS has been used extensively in metabolomics studies ([@B48]). Therefore, a metabolomics study was performed using GC--MS profiling combined with multivariate statistical analysis to monitor biomarkers and altered metabolism in serum and urine in ovalbumin (OVA) and ice water-induced cold asthma rats. We compared the effects of GJ and LGWWJX on cold asthma at the metabolite level. First, differences in metabolomic biomarkers in serum and urine were identified between the control and the treated group. Then, the effects of treatment with GJ and LGWWJX on cold asthma were evaluated. In addition, the therapeutic mechanisms of GJ and LGWWJX on cold asthma were identified by analyzing metabolic pathways.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

Male Sprague Dawley (SD) rats were purchased from the Laboratory Animal Center, Medical University of Anhui Province. All experiments were subject to approval by the Committee on the Ethics of Animal Experiments of Anhui University of Chinese Medicine. All experiments were performed in accordance with the "Regulations for the Administration of Affairs Concerning Experimental Animals" issued by the National Science and Technology Commission.

Rats from all groups were anesthetized by intraperitoneal injection with pentobarbital (50 mg narcoren/kg body weight) and fentanyl (0.05 mg/kg body weight).

Materials
---------

Ovalbumin (A5253) was purchased from Sigma Aldrich, Co., St. Louis, MO, United States, *N*-methyl-*N*-trimethylsilyl-trifluoro-acetamide (MSTFA, G35006), methoxyamine hydrochloride (90663189), and pyridine (20170104) were obtained from West Asia Chemical Industry, Co., Ltd., Shan Dong. Urease (EK170062) was supplied by Yi Ka, and methanol (20170905) and chloroform (20170321) were purchased from Sinopharm Chemical Reagent, Co., Ltd. (Beijing, China). All other chemicals were of analytical grade and used as received.

All herbs were purchased from the pharmacy of the First Affiliated Hospital of Anhui University of Chinese Medicine, and they were authenticated by Prof. Shoujin Liu (Anhui University of Chinese Medicine, Hefei, China). LGWWJX prescription contains the following five CMs:

1.  Zingiberis Rhizoma (Gan Jiang, GJ), which warms the spleen and stomach for dispelling cold, warming the lungs, and resolving retained fluid.

2.  Poria (Fu Ling, FL), which clears damp and promotes diuresis.

3.  Glycyrrhizare Radix Et Rhizoma (Gan Cao, GC), which helps to relieve coughs and reduce sputum;

4.  Asari Radix Et Rhizoma (Xi Xin, XX), which expels wind-evil and removes cold;

5.  Schisandrae Chinensis Fructus (Wu Wei Zi, WWZ), which eases coughing and tonifies kidney yang and moderates the properties of herbs.

GJ and LGWWJX Decoction Preparations
------------------------------------

Linggan Wuwei Jiangxin decoction was prepared according to the methods in our previous studies. Briefly, 20 times the minimum dose was weighed, which included Gan Jiang (180 g), Fu Ling (240 g), Gan Cao (180 g), Xi Xin (100 g), and Wu Wei Zi (100 g), and soaked in water at a 1:12 (w/v) ratio for 50 min. The water was then heated to boiling and was simmered for 40 min, then filtered. After filtration, the dregs were added to water and the above steps were repeated. The filtrates were then combined and concentrated to 2.2 g/mL. The preparation process for GJ decoction was identical to that of LGWWJX, and included 180 g of Gan Jiang. GJ was concentrated to 0.5 g/mL. GJ and LGWWJX decoctions were stored at 4°C and heated before use. The chemical components of LGWWJX decoction are shown in [Supplementary Figure S1](#SM1){ref-type="supplementary-material"} and [Supplementary Table S1](#SM5){ref-type="supplementary-material"}.

Animal Model Establishment and Assessment
-----------------------------------------

### Animal Model Establishment

Rats were randomly divided into five groups (*n* = 8 per group) as follows: control group (C), model groups (M), Gan Jiang group (GJ), LGWWJX treatment group, and positive control (Guilong Kechuanning capsule) group (PC). According to a previous study ([@B54]), rats in the M, GJ, LGWWJX, and PC groups were sensitized by intraperitoneal injections of 10% OVA (100 mg OVA, 100 mg aluminum hydroxide) in 0.5 mL of saline on the 1^st^ and 7^th^ days. The C group was injected with an equal volume of saline. On days 15--30, the M, GJ, LGWWJX, and PC groups were challenged with 1% OVA for 30 min, then subjected to a swimming test in ice water (14 ± 2°C) for 30 min. The GJ group received the Gan Jiang decoction (4.86 g/kg) by gavage, and the LGWWJX group received the LGWWJX decoction (21.6 g/kg) by gavage for 30 from the day of challenge (0.5 h after challenge). The PC group was administered Guilong Kechuanning capsule (2.43 g/kg) by gavage. The C and M groups were given distilled water. The doses of LGWWJX decoction and Guilong Kechuanning capsule were converted according to the body surface area ratio between humans and the animals in the study. The doses were sixfold than the corresponding clinical prescription dose for a 60 kg human, which is an effective moderate dose based on preliminary experiments. The dose of dry ginger was consistent with that of the amount of dried ginger in LGWWJX decoction.

### Model Assessment Indicators

General morphological observation, histopathology analysis of the lungs, inflammatory cell count in bronchoalveolar lavage fluid (BALF), IgE, IL-4, IFN-γ in serum, and visceral index were chosen as model assessment indicators.

Histopathology Analysis
-----------------------

After obtaining BALF, the upper right middle lung lobe was removed and fixed in 10% neutral buffered formalin. The specimens were dehydrated and embedded in paraffin. Five-micrometer sections of fixed embedded tissues were cut using a Leica model RM2135 rotary microtome (Leica, Nussloch, Germany) and stained with hematoxylin and eosin. Histological analyses were performed by two independent experimenters blinded to the treatment groups.

Cell Count in BALF and IgE, IL-4, and IFN-γ Detection in Serum
--------------------------------------------------------------

Rats underwent bronchoalveolar lavage with three 1-mL aliquots of ice-cold PBS via an endotracheal cannula. BALF recovery was greater than 70%. BALF was centrifuged at 1,500 rpm for 10 min at 4°C. The supernatant was discarded and the pellet was kept for further analysis. The number of total cells was counted using a hemocytometer, and cytologic classification in the bronchial alveolar lavage fluid (BALF) was determined using Wright Giemsa staining. Enzyme-linked immunosorbent assay (ELISA) (San Diego, CA, United States) was used to determine the expression levels of IgE, IL-4, and IFN-γ in serum according to the manufacturer's instructions. The absorbance was measured at 450 nm using a microplate reader (RT-6000, Leidu, United States).

Visceral Index
--------------

The hearts, livers, spleens, lungs, and kidneys of the rats were weighed. The visceral index was determined by calculating the ratios of weights of each organ to the corresponding body weights of the animals.

Serum and Urine Samples Collection
----------------------------------

The day before sacrifice, C, M, GJ, and LGWWJX rats were housed in metabolic cages (1 per cage) to collect urine for 24 h. The animals were free to drink water but were fasted. All urine samples were collected and immediately centrifuged at 3,000 rpm for 10 min at 4°C and the supernatant was stored at -80°C. The rats were then anesthetized by intraperitoneal injection of pentobarbital (50 mg narcoren/kg body weight) and fentanyl (0.05 mg/kg body weight) to obtain blood from the abdominal aorta. Blood samples were incubated for 3 h at room temperature, centrifuged at 3,000 rpm for 10 min, and the supernatants were collected and stored at -80°C.

Sample Preparation
------------------

### Serum Sample Preparation

Serum metabolites were analyzed following chemical derivatization according to a previously published procedure with minor modifications ([@B33]). One hundred microliters of thawed serum sample was added to 1.5 mL microcentrifuge tubes, followed by addition of 350 μL of methanol. The samples were vortexed for 10 s, then centrifuged at 12,000 rpm for 10 min at 4°C. A 350 μL aliquot of the supernatant was transferred into a 2 ml GC/MS glass vial and dried under nitrogen at room temperature. The residue was derivatized using a two-step procedure. First, 80 μL of methoxyamine hydrochloride (20 mg/mL in pyridine) was added to each vial, mixed gently, shaken, and incubated for 2 h at 37°C. Then, 100 μL of BSTFA (1% TMCS, v/v) was added, and the tubes were shaken and incubated for 1 h at 70°C. The derivatized samples were cooled to room temperature prior to GC--MS analysis.

### Urine Samples Preparation

Urine samples also required chemical derivatization. One hundred microliters of thawed urine was transferred to 1.5 mL eppendorf tubes and 10 μL of urease (80 mg/ml) was added. The samples were then mixed gently, shaken, and incubated for 1 h at 37°C. Next, 350 μL of methanol:chloroform (3:1, v/v) was added and the samples were vortexed for 10 s. The remaining steps were the same as those described in the serum sample derivatization preparation.

Quality Control Samples Preparation
-----------------------------------

To monitor repeatability and reliability of the method, quality control samples (QCs) were prepared by mixing equal aliquots from each serum or urine sample. QC samples were then analyzed using the same method as the prepared urine. The QC samples were injected at regular intervals (every eight samples) throughout the analytical run to provide a set of data from which repeatability and reliability could be assessed.

GC--MS Analysis
---------------

Gas chromatography--mass spectrometry analysis was performed using a Bruker 45X gas chromatograph system coupled with a SCION single quadrupole mass spectrometer (Bruker, United States).

Derivatized samples (1 μL each) were injected onto the gas chromatograph system with a split inlet equipped with a DB-5MS capillary column (30.0 μm × 250 μm inner diameter, 0.25 μm film thickness) under the following conditions: initial oven temperature was set at 50°C for 2 min, and increased to 100°C at a rate of 8°C/min, then increased to 120, 180, 200, 250 (alternate between 4 and 8°C/min), and ultimately to 280°C for 3 min. Helium was used as the carrier gas at a flow rate of 1.0 mL/min in constant flow mode and the injector split ratio was set to 20:1. The temperatures of the injector, and ion source and MS were set to 279 and 219°C, respectively. The energy was -70 eV in electron ionization mode. MS data were acquired in full-scan mode across mass-to-charge ratios (m/z) of 50--500.

Data Processing and Statistical Analysis
----------------------------------------

All the GC--MS raw files from serum and urine samples were converted to Net. CDF format using proteowizard software. Peak identification, peak alignment, and peak filtration were performed using XCMS^[1](#fn01){ref-type="fn"}^ online to obtain a data matrix composed of m/z values, retention times, ion fragments, and peak areas. Peak areas were normalized using Excel, then imported into SIMCA-P 13.0 (Umetrics AB, Umeå, Sweden), in which multivariate statistical analysis was performed. Before analysis, data were mean centered and unit variance scaled. Principal component analysis (PCA) was used to display the overall differences. Partial least-squared discrimination analysis (PLS-DA) and orthogonal projection to latent structure-discriminate analysis (OPLS-DA) were used to verify the model and explore different biomarkers between groups by incorporating known classifications. Then, the variable importance for project values (VIP) exceeding 1 were selected first and these metabolites were subsequently analyzed by paired *t*-test analysis using SPSS 23.0 (International Business Machines, Corp., Armonk, NY, United States), and *p* \< 0.05 was considered to be a significant difference. VIP \> 1 and *p* \< 0.05 were criteria for screening differential metabolites. Metabolite identification was performed by executing similarity searches in the NIST11.L mass spectral library (National Institute of Standards and Technology, Gaithersburg, MD, United States) and metabolites with a NIST match factor of ≥ 700 were investigated. One-way analysis of variance (ANOVA) (SPSS23, International Business Machines, Corp., Armonk, NY, United States) was used to evaluate pharmacodynamics effects among the four groups. All experimental data are presented as mean ± standard deviation.

Results
=======

Assessment of Cold Asthma Rats
------------------------------

### General Morphological Observation

Rats in group C moved freely, had shiny hair, and exhibited smooth breathing. Rats in the M group exhibited slow movement, nose scratching, sneezing, and wheezing, and had swollen claws, white lips, and dark hair.

### Histopathology Analysis

Pathological changes in lung tissue were assessed by hematoxylin and eosin (HE) staining of the paraffin embedded sections ([Figure 1](#F1){ref-type="fig"}). Lungs of M group animals exhibited airway wall thickening, airway luminal narrowing, inflammatory cell infiltration around mucosa of bronchioles, and epithelial cell shedding ([Figure 1B](#F1){ref-type="fig"}), which indicated that the model had been successfully established. These changes were markedly ameliorated by GJ and LGWWJX treatments, and LGWWJX exerted a greater effect.

![Pathological changes in lung tissue observed by hematoxylin and eosin (HE) staining (Light microscopy, ×200). 4.86 g/kg Gan Jiang and 21.6 g/kg of Linggan Wuwei Jiangxin (LGWWJX) decoction significantly reduced inflammation and pathological changes compared with the model group. LGWWJX decoction alleviated airway wall thickening and inflammatory cell infiltration to a greater extent than GJ. **(A)** control; **(B)** model; **(C)** Gan Jiang (GJ, 4.86 g/kg); **(D)** LGWWJX decoction (LGWWJX, 21.6 g/kg); **(E)** postive control (PC, Guilong Kechuanning, 2.43 g/kg). (a) airway wall; (b) inflammatory cell infiltration; (c) airway luminal narrowing; (d) mucous plug.](fphar-10-00284-g001){#F1}

### Cell Count in BALF and IgE, IL-4, and IFN-γ Detection in Serum

As shown in [Table 1](#T1){ref-type="table"}, total cells in BALF and the percentage of eosinophils, mononuclear and neutrophils in the M group were dramatically increased compared to that in the C group. These results are summarized in [Table 1](#T1){ref-type="table"} and [Supplementary Figure S2](#SM2){ref-type="supplementary-material"}. IgE, IL-4 were markedly increased, but IFN-γ was significantly decreased, in the M group. These results are summarized in [Supplementary Figure S3](#SM3){ref-type="supplementary-material"}. These results demonstrated that GJ and LGWWJX treatment could ameliorate inflammation associated with asthma.

###### 

Inflammatory cells and cytokines in the four groups.

  Group    Cell count in BALF   Inflammatory cytokines in serum                                                                                          
  -------- -------------------- --------------------------------- -------------------- -------------------- --------------------- ---------------------- ----------------------
  C        2.23 ± 1.27          1.06 ± 0.98                       12.50 ± 1.70         11.25 ± 1.39         102.10 ± 3.47         248.70 ± 5.02          1322.00 ± 12.61
  M        28.41 ± 3.24^\#\#^   30.44 ± 3.87^\#\#^                62.88 ± 2.13^\#\#^   25.31 ± 3.06^\#\#^   290.40 ± 5.96^\#\#^   927.50 ± 30.63^\#\#^   507.10 ± 16.16^\#\#^
  GJ       3.70 ± 1.00^∗∗^      19.81 ± 5.74^∗^                   42.73 ± 2.14^∗∗^     18.88 ± 2.12^∗∗^     232.20 ± 12.61^∗∗^    697.20 ± 21.45^∗∗^     1149.0 ± 30.59^∗∗^
  LGWWJX   3.49 ± 1.13^∗∗^      9.37 ± 1.21^∗∗^                   45.81 ± 2.25^∗∗^     13.87 ± 2.55^∗∗^     188.90 ± 3.45^∗∗^     512.60 ± 21.37^∗∗^     834.01 ± 26.37^∗∗^
  PC       2.82 ± 0.30^∗∗^      5.63 ± 0.43^∗∗^                   30.13 ± 0.59^∗∗^     13.13 ± 0.91^∗∗^     159.04 ± 2.60^∗∗^     407.10 ± 19.58^∗∗^     1113.20 ± 37.41^∗∗^

Data are represented as means ± SD.

n

= 8.

\#\#

Compared with control group,

p

\< 0.01.

∗

Compared with model group,

p

\< 0.05.

∗∗

Compared with model group,

p

\< 0.01.

### Visceral Index

As shown in [Table 2](#T2){ref-type="table"}, heart and lung indices were increased in the M group compared with the C group. No other group comparisons resulted in significant differences. Treatment with GJ and LGWWJX decoctions and PC returned heart and lung indices to normal levels.

###### 

Visceral index results.

           Heart index         Liver index      Spleen index   Lung index          Kidney index
  -------- ------------------- ---------------- -------------- ------------------- --------------
  C        0.31 ± 0.04         2.82 ± 0.32      0.23 ± 0.06    0.91 ± 0.25         0.59 ± 0.05
  M        0.38 ± 0.05^\#\#^   3.11 ± 0.24      0.30 ± 0.08    0.96 ± 0.13^\#\#^   0.63 ± 0.06
  GJ       0.35 ± 0.07^∗∗^     2.99 ± 0.35      0.24 ± 0.06    0.92 ± 0.24^∗∗^     0.63 ± 0.09
  LGWWJX   0.33 ± 0.05^∗∗^     2.85 ± 1.12      0.22 ± 0.07    0.83 ± 0.22^∗∗^     0.63 ± 0.07
  PC       0.31 ± 0.05^∗∗^     2.80 ± 0.33^∗^   0.24 ± 0.07    0.90 ± 0.26^∗∗^     0.61 ± 0.06

\(C\) Control group, (M) model group, (GJ) 4.86 g/kg Gan Jiang decoction group, (LGWWJX) 21.6 g/kg Linggan Wuwei Jiangxin decoction group, (PC) 2.43 g/kg positive control group. Data are represented as means ± SD.
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= 8.

\#\#

Compared with control group,

p

\< 0.01.

∗

Compared with model group,

p

\< 0.05.

∗∗

Compared with model group,

p

\< 0.01.

GC--MS Analysis
---------------

### QC Samples Analysis

Use of QC samples confirmed system suitability and analytical stability over the course of analytical data collection. QC data can be used as quantitative indicators of random errors or fluctuations during the analytical run. GC--MS total ion current (TIC) chromatograms of QC samples were captured ([Supplementary Figure S4](#SM4){ref-type="supplementary-material"}), and the chromatographic peaks in the QC samples nearly all agreed, indicating good stability of the instrument and method.

### GC--MS Analysis

TIC chromatograms of serum and urine from the C, M, GJ, and LGWWJX groups are shown in [Figure 2A,B](#F2){ref-type="fig"}. However, no clear differences were observed.

![Representative GC--MS TIC chromatograms of control (C), model (M), Gan Jiang (GJ) decoction, and LGWWJX decoction groups in rat serum **(A)** and urine **(B)**.](fphar-10-00284-g002){#F2}

Multivariate Statistical Analysis of Metabolites
------------------------------------------------

To evaluate metabolic profiles, PCA was performed between the C group and the M group for the serum and urine samples with the following results: *R*^2^ = 0.794 and *Q*^2^ = 0.635 for serum, and *R*^2^ = 0.713 and *Q*^2^ = 0.576 in urine, which indicated that the models were of good quality and provided accurate predictions. The score plots of PCA ([Figure 3A,B](#F3){ref-type="fig"}) showed obvious differences between the C group and the M group, which indicated that the metabolic profiles of cold asthma rats were altered. Then, PLS-DA analysis was performed, and permutation test (permutation number: 200) results were as follows: *R*^2^ = 0.442 and *Q*^2^ = -0.208 in serum, and *R*^2^ = 0.563 and *Q*^2^ = -0.0145 in urine, which demonstrated robustness and good predictive ability of the model ([Figure 3C,D](#F3){ref-type="fig"}). To screen differential metabolites and maximize discriminatory ability of serum and urine metabolites between the groups, orthogonal partial least-squares discriminant analysis (OPLS-DA) was performed. As shown in the score plot ([Figure 3E,F](#F3){ref-type="fig"}), the serum and urine samples in the M group were significantly different from those in the C group. The S-plots ([Figure 3G,H](#F3){ref-type="fig"}) showed differential metabolites between the two groups, and variable importance in the projection (VIP) was obtained based on OPLS-DA with a threshold of 1.0.

![Score plots from the PCA model of the control group (green) vs. the model group (black) for **(A)** serum and **(B)** urine. Two hundred permutations of the PLS-DA model for serum **(C)** and urine **(D)**. R^2^ (green triangle); Q^2^ (blue square). Score plots form the OPLS-DA model of the control group (C, green) vs. the model group (M, black) for serum **(E)** and urine **(F)**. S-Plots from the OPLS-DA model for serum **(G)** and urine **(H)**.](fphar-10-00284-g003){#F3}

In addition, we also investigated the differences in metabolic profiles between the M group and the GJ group, and the M group and the LGWWJX group using OPLS-DA analysis. Score 3D plots ([Figure 4A,B](#F4){ref-type="fig"}) from OPLS-DA were used to maximize discrimination of metabolite differences among the four groups. [Figure 4](#F4){ref-type="fig"} shows that the metabolomic profiles of the GJ and LGWWJX treatment groups had a tendency to return to a profile more similar to the control group, and the metabolomic profile of the LGWWJX group was closest to that of the C group. These results suggested that GJ and LGWWJX both exerted effects on metabolism in cold asthma rats, and LGWWJX exerted more powerful effects than GJ on cold asthma.

![OPLS-DA scores 3D plots. **(A)** Comparison of C (green), M (black), GJ (red), and LGWWJX (yellow) in serum (R^2^X = 0.855, R^2^Y = 0.896, Q^2^ = 0.659). **(B)** Comparison of C (green), M (black), GJ (red), and LGWWJX (yellow) in urine (R^2^X = 0.817, R^2^Y = 0.899, Q^2^ = 0.639).](fphar-10-00284-g004){#F4}

Potential Biomarkers
--------------------

Biomarkers play an important role in the diagnosis and determination of prognosis of diseases. Based on the criteria VIP \> 1, *p* \< 0.05 and NIST match factor \> 700, we identified 15 biomarkers in serum and 22 biomarkers in urine that were differentially present in the M group compared with the C group ([Table 3](#T3){ref-type="table"}). These potential biomarkers were mainly associated with carbohydrates, fatty acids, organic acids, and their products. In the M group, the majority of carbohydrates were significantly downregulated, while levels of [D]{.smallcaps}-(-)tagatose were increased and differences in glucopyranose in serum and urine were inconsistent (elevated in serum, reduced in urine), compared to the C group. Most fatty acid products were notedly upregulated in the M group, except for octadecanoic acid (serum), pentanedioic acid, and benzeneacetic acid (urine). Levels of propanoic acid, 3, 4-dihydroxybutanoic acid, and citric acid were also increased in the M group, while phosphate (3:1), glycerol, glycine, [D]{.smallcaps}-pinitol, and myoinositol were decreased in the M group compared to the C group. Intervention with GJ and LGWWJX decoctions reversed the observed changes for most of the differential metabolites, but they did not normalize glycerol (serum), hexanedioic acid, β-[D]{.smallcaps}-glucuronide, or [D]{.smallcaps}-(+)cellobiose (urine). All metabolites that were regulated by GJ were also regulated by the LGWWJX decoction. However, not all metabolites regulated by LGWWJX were regulated by GJ ([Figure 5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). LGWWJX decoction normalized differential levels of glucopyranose (serum), benzoic acid, [D]{.smallcaps}-glucose, [D]{.smallcaps}-galactose, and [D]{.smallcaps}-lactose (urine), but GJ did not normalize these metabolites. In addition, LGWWJX decoction regulated serum [D]{.smallcaps}-glucose (serum and urine) and hexadecanoic acid, and urine phosphate (3:1), butanedioic acid, β-[D]{.smallcaps}-glucopyranose, citric acid, glucaric acid, myoinositol, and maltose.

###### 

Potential biomarkers to distinguish control group rats, cold asthma rats, and rats treated with GJ and LGWWJX decoctions.

         RT/min                   Endogenous metabolites            M/Z                                                           VIP      *p*     Match   Regulation       
  ------ ------------------------ --------------------------------- ------------------------------------------------------------- -------- ------- ------- ------------ --- ---
  Sm1    5.333                    Propanoic acid                    28, 45, 73, 88, 117, 147, 191, 219                            1.23     0.000   953     ↑            ↓   ↓
  Sm2    8.449                    Glycerol                          73, 103, 133, 147, 177, 205, 218                              1.01     0.012   881     ↓            /   /
  Sm3    9.889                    Glycine                           45, 73, 86, 133, 147, 174, 188, 248, 276                      1.72     0.023   824     ↓            ↑   ↑
  Sm4    11.115                   Phosphate(3:1)                    45, 73, 133, 211, 253, 283, 299, 314                          1.43     0.015   776     ↓            ↑   ↓
  Sm5    19.798                   Heptadecane                       57, 71, 85, 99, 127, 155, 238                                 1.16     0.000   792     ↑            ↓   ↓
  Sm6    22.088                   [D]{.smallcaps}-Pinitol           73, 147, 159, 247, 260, 318, 433                              1.61     0.033   867     ↓            ↑   ↑
  Sm7    22.49                    [D]{.smallcaps}-(-)-Tagatose      15, 45, 73, 103, 133, 147, 189, 217, 307, 466                 1.96     0.000   874     ↑            ↑   ↑
  Sm8    22.634                   [D]{.smallcaps}-Mannitol          73, 103, 147, 205, 217, 319, 345                              1.18     0.000   858     ↓            ↑   ↑
  Sm9    22.853                   [D]{.smallcaps}-Galactose         45, 59, 73, 103, 129, 147, 160, 205, 217, 229, 291, 319       1.26     0.000   922     ↓            ↑   ↑
  Sm10   23.069                   [D]{.smallcaps}-Glucose           73, 103, 147, 205, 268, 319                                   1.40     0.015   922     ↓            ↑   ↑
  Sm11   24.363                   Glucopyranose                     73, 103, 129, 147, 191, 204, 217, 231                         1.16     0.004   834     ↓            /   ↑
  Sm12   25.131                   Myoinositol                       73, 103, 129, 147, 217, 305, 343, 432                         1.14     0.000   891     ↓            ↑   ↑
  Sm13   27.786                   Hexadecanoic acid                 29, 43, 73, 83, 117, 132, 145, 159, 201, 243, 269, 313, 328   1.07     0.009   899     ↑            ↓   ↓
  Sm14   32.181                   Octadecanoic acid                 43, 55, 73, 117, 132, 145, 201, 243, 269, 341, 356            1.13     0.003   887     ↓            ↑   ↑
  Sm15   38.921                   Lactose                           73, 89, 103, 147, 204, 243, 271, 319                          1.25     0.000   895     ↓            ↑   ↑
  Um1    10.938                   Phosphate(3:1)                    73, 115, 133, 211, 283, 299, 314                              1.01     0.014   938     ↓            /   ↑
  Um2    12.122 27.151            Benzoic acid                      77, 105, 117, 147, 179, 194                                   1.15     0.021   923     ↑            /   ↓
  Um3    12.932                   Butanedioic acid                  73, 129, 147, 172, 247                                        1.16     0.000   935     ↑            ↓   ↓
  Um4    14.120                   3, 4-Dihydroxyb-utanoic acid      73, 147, 189, 233, 246, 300                                   1.13     0.021   914     ↑            ↑   ↑
  Um5    16.996                   [L]{.smallcaps}-Threonic acid     73, 117, 147, 205, 292, 409                                   1.01     0.036   920     ↓            ↑   ↑
  Um6    19.630                   [D]{.smallcaps}-(+)Arabitol       73, 103, 147, 205, 217, 243, 307, 395                         1.08     0.009   913     ↓            ↑   ↑
  Um7    20.367, 20.509, 21.292   [L]{.smallcaps}(-)-Fructose       73, 89, 117, 133, 147, 201, 231                               1\. 02   0.040   867     ↓            ↑   ↑
  Um8    21.160                   Pentanedioic acid                 73, 112, 147, 186198, 229, 260, 288                           1.06     0.009   850     ↓            ↑   ↑
  Um9    21.292                   Hexanedioic acid                  73, 109, 129, 147, 203, 233, 247, 363                         1.21     0.009   774     ↑            /   /
  Um10   21.406                   Ribonic acid                      73, 103, 147, 217, 292, 307                                   1.09     0.002   909     ↓            ↑   ↑
  Um11   21.814                   Benzeneacetic acid                73, 89, 105, 147, 164, 179, 252, 281                          1.08     0.015   878     ↓            ↑   ↑
  Um12   22.380                   β-[D]{.smallcaps}-Glucopyranose   73, 147, 191, 204, 291, 345, 435                              1.42     0.000   928     ↑            ↑   ↑
  Um13   22.853                   [D]{.smallcaps}-Glucose           73, 103, 147, 160, 205, 217, 319                              1.01     0.002   923     ↓            /   ↑
  Um14   22.862                   [D]{.smallcaps}-Galactose         73, 147, 160, 205, 217, 229, 291, 319                         1.18     0.000   930     ↓            /   ↑
  Um15   23.420                   Citric acid                       73, 147, 183, 211, 231, 273, 285, 363, 465                    1.01     0.006   910     ↑            ↓   ↓
  Um16   23.958                   Glucaric acid                     73, 103, 147, 292, 333, 423                                   1.00     0.010   708     ↓            ↑   ↑
  Um17   25.138                   Myo-inositol                      73, 103, 147, 265, 305, 367, 432                              1.001    0.012   879     ↓            ↑   ↑
  Um18   25.523                   [L]{.smallcaps}-Ascorbic acid     73, 133, 147, 205, 243, 274, 361, 391                         1.08     0.042   800     ↓            ↑   ↑
  Um19   38.591                   β-Glucuronide                     73, 103, 147, 180, 257, 375                                   1.07     0.000   923     ↓            /   /
  Um20   38.821                   [D]{.smallcaps}-Lactose           73, 103, 129, 147, 204, 217, 319, 361, 392                    1.147    0.000   928     ↓            /   ↑
  Um21   39.434                   Maltose                           73, 147, 204, 217, 361, 373, 392                              1.19     0.000   824     ↓            ↑   ↑
  Um22   40.406                   [D]{.smallcaps}-(+)Cellobiose     73, 103, 147, 191, 204, 217, 243, 361, 373, 393               1.17     0.000   928     ↓            /   /

↑ Represents content increased; ↓ represents content decreased.

![Expression levels of differentially expressed metabolites in serum. **(A)** Propanoic acid; **(B)** Glycerol; **(C)** Glycine; **(D)** Phosphate (3:1); **(E)** Heptadecane; **(F)** [D]{.smallcaps}-Pinitol; **(G)** [D]{.smallcaps}-(--)Tagatose; **(H)** [D]{.smallcaps}-Mannitol; **(I)** [D]{.smallcaps}-Galactose; **(J)** [D]{.smallcaps}-Glucose; **(K)** Glucopyranose; **(L)** Myoinositol; **(M)** Hexadecanoic acid; **(N)** Octadecanoic acid; **(O)** Lactose. C, control group; M, model group; GJ, GanJiang decoction group; LGWWJX, LGWWJX decoction group. ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, compared with the control group. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, compared with the model group.](fphar-10-00284-g005){#F5}

![Levels differentially expressed metabolites in urine. **(A)** Phosphate(3:1); **(B)** Benzoic acid; **(C)** Butanedioic acid; **(D)** 3, 4-Dihydroxybutanoicacid; **(E)** [L]{.smallcaps}-threonic; **(F)** [D]{.smallcaps}-(+)arabitol; **(G)** [L]{.smallcaps}-(--)Fructose; **(H)** Pentanedioic acid; **(I)** Hexanedioic acid; **(J)** Ribonic acid; **(K)** Benzeneacetic acid; **(L)** β-[D]{.smallcaps}-Glucopyranose; **(M)** [D]{.smallcaps}-Glucose; **(N)** [D]{.smallcaps}-Galactose; **(O)** Citric acid; **(P)** Glucaric acid; **(Q)** Myoinositol; **(R)** [L]{.smallcaps}-Ascorbic acid; **(S)** β-Glucuronide; **(T)** [D]{.smallcaps}-Lactose; **(U)** Maltose; **(V)** [D]{.smallcaps}-(+)Cellobiose. C, control group; M, model group; GJ, Gan Jiang decoction group; LGWWJX, LGWWJX decoction group. ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, compared with the control group. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, compared with the model group.](fphar-10-00284-g006){#F6}

Metabolic Pathway Analysis
--------------------------

To explore the possible pathways affected by cold asthma, differential endogenous metabolites in [Table 3](#T3){ref-type="table"} were imported into MetaboAnalyst4.0^[2](#fn02){ref-type="fn"}^. The impact value threshold of pathway topology analysis was set to 0.1, and the impact value of pathways above this threshold were considered potential target pathways. As shown in [Figure 7](#F7){ref-type="fig"}, cold asthma was associated with seven key metabolic pathways, including starch and sucrose metabolism, galactose metabolism, the tricarboxylic acid cycle (TCA), glyoxylate and dicarboxylate, glycerol phospholipid metabolism, glycine, serine and threonine metabolism, and inositol phosphate metabolism.

![Summary of pathway analysis of serum and urine samples from cold asthma rats. **(a)** Starch and sucrose metabolism; **(b)** Galactose metabolism; **(c)** Tricarboxylic acid cycle; **(d)** Glyoxylate and dicarboxylate; **(e)** Glycerol phospholipid metabolism; **(f)** Glycine, serine, and threonine metabolism; **(g)** Inositol phosphate metabolism.](fphar-10-00284-g007){#F7}

Correlation Between Metabolites and Various Efficacy Indicators
---------------------------------------------------------------

A correlation map of rat serum and urine metabolites and efficacy indicators of cold asthma was generated based on Pearson's correlation coefficients. The correlation heat-map ([Figure 8](#F8){ref-type="fig"}) shows that the metabolites of Sm1, Sm5, Sm8 (serum; propanoic acid; heptadecane) were strongly positively related to the level of IL-4, eosinophils, and neutrophils (*r* = 0.645, 0.599, 0.493; 0.554, 0.582, 0.422; 0.558, 0.647, 0.563, respectively). In addition, Sm8 was also negatively associated with IFN-γ (*r* = -0.733). However, the metabolites Sm2, Sm3, Sm4, Sm9, Sm10, Sm11, Sm15 (serum glycerol, glycine, phosphate, [D]{.smallcaps}-galactose, glucose, glucopyranose, and lactose) were positively associated with IFN-γ. The metabolites Um2, Um4, and Um9 (urine benzoic acid, 3,4-dihydroxybutanoic acid, and hexanedioic acid) were positive associated with IgE (0.722, 0.605, 0.571). The metabolites Um13, Um14, Um16, Um20, Um21, and Um22 (urine [D]{.smallcaps}-glucose, [D]{.smallcaps}-galactose, glucaric acid, [D]{.smallcaps}-lactose, maltose, and [D]{.smallcaps}-(+)cellobiose) were negatively associated with IL-4, eosinophils, and neutrophils (-0.542, -0.584, -0.412; -0.669, -0.774, -0.671; -0.659, -0.707, -0.638; -0.642, -0.745, -0.607; -0.700, -0.741, -0.583; -0.743, -0.729, -0.568), and positively associated with IFN-γ (0.526; 0.538; 0.428; 0.460; 0.584; 0.522).

![Correlation map of rat serum and urine metabolites and pharmacodynamics indices according to Pearson correlation coefficients. Degrees of correlation degrees are shown using a color scale from significantly negatively correlated (blue) to significantly positively correlated (red).](fphar-10-00284-g008){#F8}

Discussion
==========

This study evaluated the protective effects of GJ and LGWWJX on cold asthma induced by OVA challenge and swimming in ice-water in rats at the metabolomics level. Seven metabolic pathways were affected in cold asthma. Based on the identified potential biomarkers and associated metabolic pathways, the observed changes were associated with energy metabolism and oxidative stress in cold asthma rats. GJ and LGWWJX reversed the majority of metabolite changes that resulted from cold asthma. LGWWJX exerted more powerful beneficial effects than GJ on cold asthma.

Energy Metabolism
-----------------

In this study, a prominent metabolic feature observed in cold asthmatic rats was a change in energy metabolism. Three major sugar metabolic pathways are involved in energy metabolism: starch and sucrose metabolism, galactose metabolism, and the TCA cycle. Carbohydrates, proteins, and fats are the main sources of energy in mammals. Previous studies showed that energy metabolism markers were reduced in urine and serum in models of experimental asthma ([@B17]; [@B18]). Carbohydrates are generally catabolized in cells via the concerted action of glycolysis and the TCA cycle under aerobic condition ([@B41]). Carbohydrates are converted to propanoic acid by pentose phosphate under anoxic conditions. In our study, elevated propanoic acid (a product of glycolysis), citric acid (a product of the TCA cycle), and butanedioic acid (succinic acid, product of the TCA cycle) demonstrated alternations in energy metabolism. These products typically accumulate during abnormal lung respiration, especially under hypoxic or inflamed conditions ([@B52]). Increased propanoic acid levels have been reported in the serum of adults with asthma, in the urine of children with asthma, and in BALF from patients with cystic fibrosis ([@B20]; [@B1]; [@B36]). Citric acid is a metabolic product carbohydrate breakdown via the TCA cycle that provides additional energy in the form of adenosine triphosphate (ATP). Increased citric acid has been reported in the plasma of adults with cystic fibrosis during pulmonary crises and in the urine of asthmatic rats, which demonstrated consistent impairment of energy metabolism in these respiratory diseases ([@B34]). Elevated levels of butanedioic acid (succinic acid) were observed in the serum of patients with moderate asthma, and in the urine of children with asthma ([@B20]; [@B34]; [@B6]). In addition, we found that levels of 3,4-dihydroxybutanoic acid were also elevated in the M group, which could indicate energy metabolism disorders related to the increased ketone bodies (β-oxidation products of free fatty acids), which can provide energy to organs such as the brain when carbohydrate stores are depleted ([@B53]). In addition, significant correlations have been observed between energy metabolism metabolites and inflammatory cells in asthma, supporting a relationship between energy metabolism and inflammation. In this study, carbohydrate-related metabolites such as [D]{.smallcaps}-galactose, [D]{.smallcaps}-glucose, glucopyranose, [D]{.smallcaps}-mannitol, lactose, and other metabolites were decreased in the model group rats compared with the control group rats. These sugar and sugar alcohols might have been broken down into propanoic acid, citric acid, and butanedioic acid to provide additional energy, consistent with results from a previous study ([@B18]). Changes in energy metabolism were the main characteristics in this study, which may have been related to increased respiratory burden, and increased use of energy to recruit inflammatory cells and support increased energy demands to maintain body temperature in cold asthma rats. GJ and LGWWJX decoctions normalized the majority of metabolites altered in the cold asthma model, and LGWWJX exerted more powerful effects than GJ on energy metabolism. This difference might have been due to the change of property of warming and the complex chemical composition under the compatibility of GJ in LGWWJX. [@B8] showed that the active components in dried ginger for treatment of cold-related lung fluid retention in rats with COPD have different tissue distribution.

Oxidative Stress
----------------

Oxidative stress is closely associated with asthma ([@B43]; [@B47]; [@B10]). Inflammatory cells such as eosinophils and neutrophils release reactive oxygen species (ROS) in asthmatic patients ([@B12]). Reduction in antioxidant capacity and overproduction of ROS results in redox imbalance. ROS contribute to the pathogenesis of asthma through pulmonary function impairment, mast cell degranulation, airway remodeling, and mucus secretion by epithelium, which results in aggravation of local inflammation the lung ([@B55]). In this study, three pathways may have been involved in cold asthma-related oxidative stress: lipid peroxidation, glycine, serine, and threonine metabolism, and inositol phosphate metabolism.

Lipid Peroxidation
------------------

Lipid peroxidation is a consequence of oxidative stress characterized by degradation of polyunsaturated fatty acids into volatile organic acids (VOCs), such as benzoic acid, glutaric acid, and heptaric acid, alkanes, and aldehydes, which are exlahed via the lungs ([@B5]; [@B11]; [@B55]). [@B28] examined the relationship between oxidative stress, eosinophilic inflammation, and disease severity in asthmatic patients through a metabolomics study of alkanes and aldehydes. This study demonstrated that increased alkanes and aldehydes positively correlated with asthma severity and eosinophils. Increased benzoic acid, hexanedioic acid, (urine), heptadecane, and hexadecenoic acid (serum), and decreased octadecanoic acid (serum), pentanedioic acid, and benzeneacetic acid (urine) in the M group in our study indicated abnormal lipid peroxidation, which may have been related to oxidative stress in cold asthma. Increased levels alkanes and aldehydes were also reported to be related to severity of asthma ([@B27]). In addition, a significant correlation was observed between heptadecane, benzoic acid, and hexanedioic acid, and inflammatory cells in asthma, which suggested that oxidative stress may play a role in the pathogenesis of cold asthma. GJ and LGWWJX reversed these changes, and the effect of LGWWJX decoction was more pronounced than that of GJ.

The Glycine, Serine, and Threonine Metabolism Pathway
-----------------------------------------------------

Glycine, serine, and threonine are closely related amino acids that share common biochemical pathways. Glycine can be converted to serine, then choline and cholamine, which participate in the biosynthesis of purines and pyrimidines. [@B51] studied the cytoprotective effects of glycine and indicated that glycine inhibits oxidative stress through enhancing intracellular glutathione concentrations in IPEC-1 cells. [@B24] found that glycine can reduce inflammatory mediators and ROS. [@B14] showed that glycine can significantly reduce lung injury by inhibiting inflammatory cell aggregation and attenuating lipid peroxidation. In our study, glycine levels were decreased in the serum of cold asthma rats and the glycine, serine, and threonine metabolic pathway was disrupted. In addition, glycine, phosphate (3:1), glycerol, and myoinositol are raw materials for synthesis of phospholipids, which are important components of cell membranes. Reduced levels of these metabolites reflected decreased phospholipid synthesis. We speculated that reduced glycine in cold asthma rats may have been related to oxidative stress and inflammatory cell infiltration, but the specific mechanisms have not been characterized.

Inositol Phosphate Metabolism
-----------------------------

Altered levels of myoinositol are related to inositol phosphate metabolism. Phosphatidylinositol 3-kinases (PI3K), a key element in inositol phosphate metabolism, generates lipid second messengers that control an array of intracellular signaling pathways which play important roles in inflammation. A previous study showed that oxidative stress is associated with the PI3K signaling pathway. [@B31] showed that artesunate can suppress cigarette smoke-induced airway inflammation and oxidative damage in mice, likely via inhibition of the PI3K signaling pathway. [@B40] showed that formoterol reversed oxidative stress-induced corticosteroid insensitivity and decreased β2 adrenoceptor-dependent cAMP production via inhibition of PI3K signaling, which suggested a relationship between oxidative stress and the PI3K pathway. Other factors related to inositol phosphate metabolism are also strongly associated with asthma. [@B30] showed that long-chain free fatty acid binding to fatty acid receptors increased inositol phosphate synthesis in human airway smooth muscle cells (hASM). [@B4] showed that flavonols significantly inhibited purified phosphodiesterase-4 (PDE4) and PLCβ enzymes, attenuated acetylcholine-induced increases in inositol phosphates and CPI-17 phosphorylation in hASM cells and relaxed airway smooth muscle. These studies indicated the crucial role of inositol phosphate metabolism in asthma. In our study, decreased myoinositol and pathway analysis suggested disruption of inositol phosphate metabolism was a characteristic of cold asthma, and GJ and LGWWJX both normalized myoinositol levels. However, the specific mechanisms of these effects have not been characterized.

Other Metabolites
-----------------

In addition to metabolites that contribute to energy metabolism and oxidative stress, other metabolites were associated with cold asthma. [L]{.smallcaps}-Ascorbic acid (vitamin C) is an important low molecular weight antioxidant that maintains antioxidative defenses at the air-lung interface ([@B32]). Previous studies have shown that lower levels of essential antioxidants in circulation were associated with increased risk of disease ([@B29]; [@B42]; [@B2]). Absorption of ascorbic acid in the small intestine occurs primarily through Na^+^-dependent active transport ([@B37]). In this study, reduced [L]{.smallcaps}-ascorbic acid suggested alterations in the antioxidant defense system, which can result in oxidative stress. Previous reports showed that vitamin C can reduce histamine, which results in mast cell degranulation allergic reactions, but the mechanisms that result in these allergic effects have not been characterized ([@B15]; [@B39]). [@B49] observed ascorbate deficiency in patients with allergic diseases and treatment with intravenous high-dose vitamin C reduced allergy-related symptoms. In addition, in our study, the level of [D]{.smallcaps}-pinitol was also decreased. [D]{.smallcaps}-pinitol exerts insulin-like effects via facilitation of transport of creatine and other nutrients into muscle cells ([@B9]). [D]{.smallcaps}-Pinitol also exhibits anti-inflammatory activity and can contribute to prevention of cardiovascular diseases ([@B45]; [@B22]). [@B23] showed that [D]{.smallcaps}-pinitol reduces allergic airway inflammation and hyperresponsiveness due to alteration of Th1/Th2 polarization via suppression of GATA-3 and increased T-bet expression. In our study, GJ and LGWWJX decoctions normalized [L]{.smallcaps}-ascorbic acid and [D]{.smallcaps}-pinitol in M group rats, but the mechanisms were not clear.

Cold Asthma
-----------

Cold weather affects the respiratory epithelium and induces bronchial hyperresponsiveness ([@B26]; [@B7]). Cold weather further aggravates respiratory symptoms in asthma ([@B19]). Cold asthma is a syndrome diagnosed in CM clinics. CM doctors postulate that cold will injure the spleen, and chronic spleen injury will increase sputum drinking, which accumulates in the lung, resulting in asthma. As such, CM doctors advocate for "warming the stomach to dispel cold, warming the lung to resolve fluid" to treat cold asthma. GJ has warm and spicy properties and it is often used in combination with other herbs to treat cold asthma in clinics. LGWWJX, which contains GJ, is the main prescription for treating cold asthma. In this prescription, GJ is the main component and it can warm the lung and spleen. Asari Radix Et Rhizoma helps GJ to warm the lung, Poria helps GJ tonify the spleen and dissipate excessive fluid, Schisandrae Chinensis Fructus astringes the lung to stop cough, and Glycyrrhizare Radix Et Rhizoma moderates the properties of the herbs.

It is generally accepted that the effects of CM prescriptions are closely related to their chemical compositions. As such, modern research has also focused on chemical characterization of Chinese remedies. Gingerols, major medicinal ingredients in dried ginger, exert antipyretic, analgesic, anti-inflammatory, and antioxidant effects ([@B3]; [@B46]; [@B25]). A previous study reported that drying temperature of ginger results in conversion of gingerols to shogaols, resulting in increased antioxidant and antimicrobial activities ([@B13]). In our previous study, we found that other herbs in LGWWJX decoction combined with dried ginger affected the concentrations of 6-gingerol, 8-gingerol, 6-shogao, and 10-gingerol ([@B38]). However, it is difficult to characterize the interactions between GJ and other herbs in LGWWJX decoction, and to determine which components have the greatest effects on cold asthma. However, the advantages of metabolomics were apparent in this study.

Conclusion
==========

In this study, serum and urine metabolites identified by GC--MS and general pharmacodynamic evaluation (morphological observation, histopathology, inflammatory factors, and visceral indices) were used to compare the effects of GJ and LGWWJX decoctions on cold asthma. Significant metabolic abnormalities were observed for 37 metabolites (15 in serum, 22 in urine) in rats with cold asthma. These altered metabolites might be potential biomarkers or therapeutic targets during development of cold asthma. Furthermore, pathway analysis demonstrated that pathways associated with energy metabolism and oxidative stress were disrupted in rats with cold asthma. GJ and LGWWJX regulated metabolites associated with various pathways. We demonstrated that the CM prescription LGWWJX exerted stronger effects than the single herb, GJ, at the metabolite level. However, the specific mechanisms of compatibility of these Chinese Medicines requires further study.
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